Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech:Industry Trends, Size and Shares Research Report @ http://www.researchmoz.us/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html
2024 State of Marketing Report – by HubspotMarius Sescu
https://www.hubspot.com/state-of-marketing
· Scaling relationships and proving ROI
· Social media is the place for search, sales, and service
· Authentic influencer partnerships fuel brand growth
· The strongest connections happen via call, click, chat, and camera.
· Time saved with AI leads to more creative work
· Seeking: A single source of truth
· TLDR; Get on social, try AI, and align your systems.
· More human marketing, powered by robots
ChatGPT is a revolutionary addition to the world since its introduction in 2022. A big shift in the sector of information gathering and processing happened because of this chatbot. What is the story of ChatGPT? How is the bot responding to prompts and generating contents? Swipe through these slides prepared by Expeed Software, a web development company regarding the development and technical intricacies of ChatGPT!
Product Design Trends in 2024 | Teenage EngineeringsPixeldarts
The realm of product design is a constantly changing environment where technology and style intersect. Every year introduces fresh challenges and exciting trends that mold the future of this captivating art form. In this piece, we delve into the significant trends set to influence the look and functionality of product design in the year 2024.
How Race, Age and Gender Shape Attitudes Towards Mental HealthThinkNow
Mental health has been in the news quite a bit lately. Dozens of U.S. states are currently suing Meta for contributing to the youth mental health crisis by inserting addictive features into their products, while the U.S. Surgeon General is touring the nation to bring awareness to the growing epidemic of loneliness and isolation. The country has endured periods of low national morale, such as in the 1970s when high inflation and the energy crisis worsened public sentiment following the Vietnam War. The current mood, however, feels different. Gallup recently reported that national mental health is at an all-time low, with few bright spots to lift spirits.
To better understand how Americans are feeling and their attitudes towards mental health in general, ThinkNow conducted a nationally representative quantitative survey of 1,500 respondents and found some interesting differences among ethnic, age and gender groups.
Technology
For example, 52% agree that technology and social media have a negative impact on mental health, but when broken out by race, 61% of Whites felt technology had a negative effect, and only 48% of Hispanics thought it did.
While technology has helped us keep in touch with friends and family in faraway places, it appears to have degraded our ability to connect in person. Staying connected online is a double-edged sword since the same news feed that brings us pictures of the grandkids and fluffy kittens also feeds us news about the wars in Israel and Ukraine, the dysfunction in Washington, the latest mass shooting and the climate crisis.
Hispanics may have a built-in defense against the isolation technology breeds, owing to their large, multigenerational households, strong social support systems, and tendency to use social media to stay connected with relatives abroad.
Age and Gender
When asked how individuals rate their mental health, men rate it higher than women by 11 percentage points, and Baby Boomers rank it highest at 83%, saying it’s good or excellent vs. 57% of Gen Z saying the same.
Gen Z spends the most amount of time on social media, so the notion that social media negatively affects mental health appears to be correlated. Unfortunately, Gen Z is also the generation that’s least comfortable discussing mental health concerns with healthcare professionals. Only 40% of them state they’re comfortable discussing their issues with a professional compared to 60% of Millennials and 65% of Boomers.
Race Affects Attitudes
As seen in previous research conducted by ThinkNow, Asian Americans lag other groups when it comes to awareness of mental health issues. Twenty-four percent of Asian Americans believe that having a mental health issue is a sign of weakness compared to the 16% average for all groups. Asians are also considerably less likely to be aware of mental health services in their communities (42% vs. 55%) and most likely to seek out information on social media (51% vs. 35%).
AI Trends in Creative Operations 2024 by Artwork Flow.pdfmarketingartwork
This article is all about what AI trends will emerge in the field of creative operations in 2024. All the marketers and brand builders should be aware of these trends for their further use and save themselves some time!
2024 State of Marketing Report – by HubspotMarius Sescu
https://www.hubspot.com/state-of-marketing
· Scaling relationships and proving ROI
· Social media is the place for search, sales, and service
· Authentic influencer partnerships fuel brand growth
· The strongest connections happen via call, click, chat, and camera.
· Time saved with AI leads to more creative work
· Seeking: A single source of truth
· TLDR; Get on social, try AI, and align your systems.
· More human marketing, powered by robots
ChatGPT is a revolutionary addition to the world since its introduction in 2022. A big shift in the sector of information gathering and processing happened because of this chatbot. What is the story of ChatGPT? How is the bot responding to prompts and generating contents? Swipe through these slides prepared by Expeed Software, a web development company regarding the development and technical intricacies of ChatGPT!
Product Design Trends in 2024 | Teenage EngineeringsPixeldarts
The realm of product design is a constantly changing environment where technology and style intersect. Every year introduces fresh challenges and exciting trends that mold the future of this captivating art form. In this piece, we delve into the significant trends set to influence the look and functionality of product design in the year 2024.
How Race, Age and Gender Shape Attitudes Towards Mental HealthThinkNow
Mental health has been in the news quite a bit lately. Dozens of U.S. states are currently suing Meta for contributing to the youth mental health crisis by inserting addictive features into their products, while the U.S. Surgeon General is touring the nation to bring awareness to the growing epidemic of loneliness and isolation. The country has endured periods of low national morale, such as in the 1970s when high inflation and the energy crisis worsened public sentiment following the Vietnam War. The current mood, however, feels different. Gallup recently reported that national mental health is at an all-time low, with few bright spots to lift spirits.
To better understand how Americans are feeling and their attitudes towards mental health in general, ThinkNow conducted a nationally representative quantitative survey of 1,500 respondents and found some interesting differences among ethnic, age and gender groups.
Technology
For example, 52% agree that technology and social media have a negative impact on mental health, but when broken out by race, 61% of Whites felt technology had a negative effect, and only 48% of Hispanics thought it did.
While technology has helped us keep in touch with friends and family in faraway places, it appears to have degraded our ability to connect in person. Staying connected online is a double-edged sword since the same news feed that brings us pictures of the grandkids and fluffy kittens also feeds us news about the wars in Israel and Ukraine, the dysfunction in Washington, the latest mass shooting and the climate crisis.
Hispanics may have a built-in defense against the isolation technology breeds, owing to their large, multigenerational households, strong social support systems, and tendency to use social media to stay connected with relatives abroad.
Age and Gender
When asked how individuals rate their mental health, men rate it higher than women by 11 percentage points, and Baby Boomers rank it highest at 83%, saying it’s good or excellent vs. 57% of Gen Z saying the same.
Gen Z spends the most amount of time on social media, so the notion that social media negatively affects mental health appears to be correlated. Unfortunately, Gen Z is also the generation that’s least comfortable discussing mental health concerns with healthcare professionals. Only 40% of them state they’re comfortable discussing their issues with a professional compared to 60% of Millennials and 65% of Boomers.
Race Affects Attitudes
As seen in previous research conducted by ThinkNow, Asian Americans lag other groups when it comes to awareness of mental health issues. Twenty-four percent of Asian Americans believe that having a mental health issue is a sign of weakness compared to the 16% average for all groups. Asians are also considerably less likely to be aware of mental health services in their communities (42% vs. 55%) and most likely to seek out information on social media (51% vs. 35%).
AI Trends in Creative Operations 2024 by Artwork Flow.pdfmarketingartwork
This article is all about what AI trends will emerge in the field of creative operations in 2024. All the marketers and brand builders should be aware of these trends for their further use and save themselves some time!
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
A report by thenetworkone and Kurio.
The contributing experts and agencies are (in an alphabetical order): Sylwia Rytel, Social Media Supervisor, 180heartbeats + JUNG v MATT (PL), Sharlene Jenner, Vice President - Director of Engagement Strategy, Abelson Taylor (USA), Alex Casanovas, Digital Director, Atrevia (ES), Dora Beilin, Senior Social Strategist, Barrett Hoffher (USA), Min Seo, Campaign Director, Brand New Agency (KR), Deshé M. Gully, Associate Strategist, Day One Agency (USA), Francesca Trevisan, Strategist, Different (IT), Trevor Crossman, CX and Digital Transformation Director; Olivia Hussey, Strategic Planner; Simi Srinarula, Social Media Manager, The Hallway (AUS), James Hebbert, Managing Director, Hylink (CN / UK), Mundy Álvarez, Planning Director; Pedro Rojas, Social Media Manager; Pancho González, CCO, Inbrax (CH), Oana Oprea, Head of Digital Planning, Jam Session Agency (RO), Amy Bottrill, Social Account Director, Launch (UK), Gaby Arriaga, Founder, Leonardo1452 (MX), Shantesh S Row, Creative Director, Liwa (UAE), Rajesh Mehta, Chief Strategy Officer; Dhruv Gaur, Digital Planning Lead; Leonie Mergulhao, Account Supervisor - Social Media & PR, Medulla (IN), Aurelija Plioplytė, Head of Digital & Social, Not Perfect (LI), Daiana Khaidargaliyeva, Account Manager, Osaka Labs (UK / USA), Stefanie Söhnchen, Vice President Digital, PIABO Communications (DE), Elisabeth Winiartati, Managing Consultant, Head of Global Integrated Communications; Lydia Aprina, Account Manager, Integrated Marketing and Communications; Nita Prabowo, Account Manager, Integrated Marketing and Communications; Okhi, Web Developer, PNTR Group (ID), Kei Obusan, Insights Director; Daffi Ranandi, Insights Manager, Radarr (SG), Gautam Reghunath, Co-founder & CEO, Talented (IN), Donagh Humphreys, Head of Social and Digital Innovation, THINKHOUSE (IRE), Sarah Yim, Strategy Director, Zulu Alpha Kilo (CA).
Trends In Paid Search: Navigating The Digital Landscape In 2024Search Engine Journal
The search marketing landscape is evolving rapidly with new technologies, and professionals, like you, rely on innovative paid search strategies to meet changing demands.
It’s important that you’re ready to implement new strategies in 2024.
Check this out and learn the top trends in paid search advertising that are expected to gain traction, so you can drive higher ROI more efficiently in 2024.
You’ll learn:
- The latest trends in AI and automation, and what this means for an evolving paid search ecosystem.
- New developments in privacy and data regulation.
- Emerging ad formats that are expected to make an impact next year.
Watch Sreekant Lanka from iQuanti and Irina Klein from OneMain Financial as they dive into the future of paid search and explore the trends, strategies, and technologies that will shape the search marketing landscape.
If you’re looking to assess your paid search strategy and design an industry-aligned plan for 2024, then this webinar is for you.
5 Public speaking tips from TED - Visualized summarySpeakerHub
From their humble beginnings in 1984, TED has grown into the world’s most powerful amplifier for speakers and thought-leaders to share their ideas. They have over 2,400 filmed talks (not including the 30,000+ TEDx videos) freely available online, and have hosted over 17,500 events around the world.
With over one billion views in a year, it’s no wonder that so many speakers are looking to TED for ideas on how to share their message more effectively.
The article “5 Public-Speaking Tips TED Gives Its Speakers”, by Carmine Gallo for Forbes, gives speakers five practical ways to connect with their audience, and effectively share their ideas on stage.
Whether you are gearing up to get on a TED stage yourself, or just want to master the skills that so many of their speakers possess, these tips and quotes from Chris Anderson, the TED Talks Curator, will encourage you to make the most impactful impression on your audience.
See the full article and more summaries like this on SpeakerHub here: https://speakerhub.com/blog/5-presentation-tips-ted-gives-its-speakers
See the original article on Forbes here:
http://www.forbes.com/forbes/welcome/?toURL=http://www.forbes.com/sites/carminegallo/2016/05/06/5-public-speaking-tips-ted-gives-its-speakers/&refURL=&referrer=#5c07a8221d9b
ChatGPT and the Future of Work - Clark Boyd Clark Boyd
Everyone is in agreement that ChatGPT (and other generative AI tools) will shape the future of work. Yet there is little consensus on exactly how, when, and to what extent this technology will change our world.
Businesses that extract maximum value from ChatGPT will use it as a collaborative tool for everything from brainstorming to technical maintenance.
For individuals, now is the time to pinpoint the skills the future professional will need to thrive in the AI age.
Check out this presentation to understand what ChatGPT is, how it will shape the future of work, and how you can prepare to take advantage.
A brief introduction to DataScience with explaining of the concepts, algorithms, machine learning, supervised and unsupervised learning, clustering, statistics, data preprocessing, real-world applications etc.
It's part of a Data Science Corner Campaign where I will be discussing the fundamentals of DataScience, AIML, Statistics etc.
Time Management & Productivity - Best PracticesVit Horky
Here's my presentation on by proven best practices how to manage your work time effectively and how to improve your productivity. It includes practical tips and how to use tools such as Slack, Google Apps, Hubspot, Google Calendar, Gmail and others.
The six step guide to practical project managementMindGenius
The six step guide to practical project management
If you think managing projects is too difficult, think again.
We’ve stripped back project management processes to the
basics – to make it quicker and easier, without sacrificing
the vital ingredients for success.
“If you’re looking for some real-world guidance, then The Six Step Guide to Practical Project Management will help.”
Dr Andrew Makar, Tactical Project Management
Unlocking the Power of ChatGPT and AI in Testing - A Real-World Look, present...Applitools
During this webinar, Anand Bagmar demonstrates how AI tools such as ChatGPT can be applied to various stages of the software development life cycle (SDLC) using an eCommerce application case study. Find the on-demand recording and more info at https://applitools.info/b59
Key takeaways:
• Learn how to use ChatGPT to add AI power to your testing and test automation
• Understand the limitations of the technology and where human expertise is crucial
• Gain insight into different AI-based tools
• Adopt AI-based tools to stay relevant and optimize work for developers and testers
* ChatGPT and OpenAI belong to OpenAI, L.L.C.
More than Just Lines on a Map: Best Practices for U.S Bike Routes
This session highlights best practices and lessons learned for U.S. Bike Route System designation, as well as how and why these routes should be integrated into bicycle planning at the local and regional level.
Presenters:
Presenter: Kevin Luecke Toole Design Group
Co-Presenter: Virginia Sullivan Adventure Cycling Association
Ride the Storm: Navigating Through Unstable Periods / Katerina Rudko (Belka G...DevGAMM Conference
Has your project been caught in a storm of deadlines, clashing requirements, and the need to change course halfway through? If yes, then check out how the administration team navigated through all of this, relocating 160 people from 3 countries and opening 2 offices during the most turbulent time in the last 20 years. Belka Games’ Chief Administrative Officer, Katerina Rudko, will share universal approaches and life hacks that can help your project survive unstable periods when there seem to be too many tasks and a lack of time and people.
This presentation was designed to provide strategic recommendations for a brand in decline. The deck also incorporates a situational assessment, including a brand identity, positioning, architecture, and portfolio strategy for the Brand.
Presentation originally created for NYU Stern's Brand Strategy course. Design by Erica Santiago & Chris Alexander.
Good Stuff Happens in 1:1 Meetings: Why you need them and how to do them wellSaba Software
According to the latest State of the American Manager report from Gallup, employees who have regular meetings with their managers are almost three times as likely to be engaged as those who don’t. These regular check-ins keep managers and employees in sync and aligned. Want to see better manager/employee relationships in your organisation? Then make an all-in commitment to 1:1 meetings. Not sure how? You’ve come to the right place.
In this webinar with Jamie Resker, Founder and Practice Leader for Employee Performance Solutions (EPS), and Teala Wilson, Talent Management Consultant at Saba Software, you’ll get the inside track on how to hold effective 1:1 meetings, including tips for getting managers on board.
• Go beyond discussing the status of everyday work to higher level topics, including recognition, performance, development, and career aspirations
• Learn how to decide meeting frequency, what to cover, as well as roles and responsibilities of the manager and employee
• Understand how managers can build trust and make it comfortable for employees to provide upward feedback
• Unite your organisation with a unified approach to 1:1 meetings
Join us for this 1-hour webinar to get practical tips for building better manager-employee relationships with intention and purpose.
About the Speakers
Jamie Resker - Founder and Practice Leader for Employee Performance Solutions (EPS)
Jamie Resker, Practice Leader and Founder of Employee Performance Solutions, is a recognized innovator in performance management. She is the originator of the-the Performance Continuum Feedback Method® and Conversations to Optimize Employee Performance training program; tools and training that reshape communications between managers and employees to drive and align performance. Jamie is on the faculty for the Northeast Human Resources Association, is a contributor to Halogen Software's Talent Space Blog, and is an editorial advisory board member for HR Examiner.
Teala Wilson - Senior Consultant, Strategic Services, Saba Software
Teala is a Talent Management Consultant at Halogen Software, now a part of Saba Software. She has worked with teams on a national and global level supporting human resources in areas such as performance management, recruitment, employee benefit programs, training and talent development, workforce planning and internal communications. Teala also has a personal passion for visual arts and design.
Want to learn more? Join us for an upcoming Product Tour!
http://bit.ly/2yitfqu
Good Stuff Happens in 1:1 Meetings: Why you need them and how to do them well
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech:Industry Trends, Size and Shares Research Report
1. Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and
unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The
majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent,
starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms
provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies
will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight
where press releases do not. This report contains over 8,000 links to online copies of actual discovery, preclinical and clinical stage deals and contract
documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions
about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to
derive value from the deal. The initial chapters of this report provide an orientation of discovery, preclinical and clinical stage deal making and business
activities.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of why companies partner discovery, preclinical and clinical stage compounds/products. Chapter 3 provides an overview of
discovery, preclinical and clinical stage deals strategy and deal structure including numerous case studies.
Chapter 4 provides an overview of the various payment strategies used in discovery, preclinical and clinical stage deals. Chapters 5 to 7 provide a review of
discovery, preclinical and clinical stage deal making since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active
of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 8 provides a
detailed analysis of discovery, preclinical and clinical stage payment terms including average headline, upfront, milestone and royalty rates for discovery deals.
Chapter 9 provides a review of the leading discovery, preclinical and clinical stage deal by headline value. Chapter 10 provides a comprehensive listing of the
top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of discovery, preclinical and clinical stage deals, as well
as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document,
providing easy access to each contract document on demand. Chapters 11 to 13 provides a comprehensive and detailed review of discovery, preclinical and
clinical stage partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by
company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via
Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The
report also includes numerous tables and figures that illustrate the trends and activities in discovery, preclinical and clinical stage partnering and deal making
since 2009. In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal
title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on
demand. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and
commercialization of discovery, preclinical and clinical stage products and compounds.
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:
In-depth understanding of discovery, preclinical and clinical stage deal trends since 2009 Access to headline, upfront, milestone and royalty data Analysis of the
structure of discovery, preclinical and clinical stage agreements with numerous real life case studies Detailed access to actual discovery, preclinical and clinical
stage deals entered into by the leading fifty big pharma and big biotech companies Insight into the terms included in a discovery, preclinical and clinical stage
agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to
assess suitability of your proposed deal terms for partner companies
Report scope Discovery, Preclinical and Clinical Stage Partnering Terms and
Agreements Terms and Agreements in Pharm and Biotech is intended to provide the reader with an in-depth understanding and access to discovery, preclinical
and clinical stage deal trends and structure of deals entered into by leading companies worldwide. Discovery, Preclinical and Clinical Stage Partnering Terms
and Agreements in Pharma and Biotech includes: Trends in discovery, preclinical and clinical stage dealmaking in the biopharma industry since 2009 Analysis
of discovery, preclinical and clinical stage deal structure Access to headline, upfront, milestone and royalty data Case studies of real-life discovery, preclinical
and clinical stage deals Access to over 8,000 discovery, preclinical and clinical stage deals The leading discovery, preclinical and clinical stage deals by value
since 2009 Most active discovery, preclinical and clinical stage dealmakers since 2009 The leading discovery, preclinical and clinical stage partnering resources
In Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by: Company A-Z
Headline value Stage of development at signing Deal type Specific therapy target Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract document on demand. The Discovery, Preclinical and Clinical Stage Partnering
Terms and Agreements in Pharma and biotech report provides comprehensive access to available deals and contract documents for over 8,000 discovery,
preclinical and clinical stage deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How aresalesand
payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for
commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be
resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting
provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type? Which jurisdiction does the company insist upon for agreement law?
table Of Content
executive Summary
chapter 1 – Introduction
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
2. chapter 2 – Why Do Company’s Partner Discovery, Preclinical And Clinical Stage Compounds?
2.1. Introduction
2.2. The Role Of Discovery, Preclinical And Clinical Stage Partnering
2.2.1. In-licensing At Clinical Stage
2.2.2. Out-licensing At Discovery Stage
2.2.3. Out-licensing At Clinical Stage
2.3. Difference Between Discovery, Preclinical And Clinical Stage Deals
2.4. Reasons For Entering Into Discovery, Preclinical And Clinical Stage Partnering Deals
2.4.1. Licensors Reasons For Entering Discovery, Preclinical And Clinical Stage Deals
2.4.2. Licensees Reasons For Entering Discovery, Preclinical And Clinical Stage Deals
2.5. The Future Of Discovery, Preclinical And Clinical Stage Partnering Deals
chapter 3 – Discovery, Preclinical And Clinical Stage Deal Strategies And Structure
3.1. Introduction
3.2. At What Stage Do Companies Partner?
3.2.1. Partnering Early In Pharmaceutical/biotech
3.2.1.1. Discovery And Preclinical Stage Partnering Case Studies
3.2.1.1.a. Case Study: Leo Pharma - 4sc
3.2.1.1.b. Case Study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case Study: Pfizer - Repligen
3.2.1.1.d. Case Study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering Later In Pharmaceutical/biotech
3.2.2.1. Clinical Stage Partnering Case Studies
3.2.2.1.a. Case Study: Roche – Genentech - Chiasma
3.2.2.1.b. Case Study: Teva – Xenon Pharmaceuticals
3.2.2.1.c. Case Study: Astrazeneca - Ardelyx
3.2.2.1.d. Case Study: Baxter – Onconova Therapeutics
3.3. Early And Later Stage Partnering – A Risk/cost Comparison
3.4. What Do Companies Spend On Discovery, Preclinical And Clinical Stage Partnering?
3.5. Pure Versus Multi-component Partnering Deals
3.6. Pure Licensing Agreement Structure
3.6.1. Example Pure Licensing Agreements
3.6.1.a. Case Study : Coley Pharmaceutical – Dynavax Technologies
3.6.1.b. Case Study : Bristol-myers Squibb - Pharmacopeia
3.7. Multicomponent Partnering Agreements
3.7.1. Example Multicomponent Deal Clauses
3.7.1.a. Case Study: Idera – Merck Kgaa
chapter 4 – Discovery, Preclinical And Clinical Stage Partnering Payment Strategies
4.1. Introduction
4.2. Discovery, Preclinical And Clinical Stage Payment Strategies
4.3. Payment Options
4.3.1. Headline Values
4.3.2. Upfront Payments
4.3.2.1. Conditionality Of Upfront Payments
4.3.3. Loans
4.3.4. Convertible Loans
4.3.5. Equity
4.3.6. R&d Funding
4.3.7. Licensing Fees
4.3.8. Milestone Payments
4.3.9. Royalty Payments
4.3.9.1. Issues Affecting Royalty Rates
4.3.9.2. Royalties On Combination Products
4.3.9.2.a. Case Study: Scripps Research Institute-cyanotech
4.3.9.3. Guaranteed Minimum/maximum Annual Payments
4.3.9.4. Royalty Stacking
4.3.9.5. Royalties And Supply/purchase Contracts
4.3.10. Quids
4.3.11. Option Payments
chapter 5 – Trends In Discovery Stage Deal Making
5.1. Introduction
5.2. Discovery Stage Partnering Over The Years
5.2.1. Attributes Of Discovery Deals
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
3. 5.3. Big Pharma Discovery Stage Dealmaking Activity
5.4. Big Biotech Discovery Stage Dealmaking Activity
5.5. Discovery Stage Partnering By Deal Type
5.6. Discovery Stage Partnering By Disease Type
5.7. Partnering By Discovery Stage Technology Type
chapter 6 – Trends In Preclinical Stage Deal Making
6.1. Introduction
6.2. Preclinical Stage Partnering Over The Years
6.2.1. Attributes Of Preclinical Deals
6.3. Big Pharma Preclinical Stage Dealmaking Activity
6.4. Big Biotech Preclinical Stage Dealmaking Activity
6.5. Preclinical Stage Partnering By Deal Type
6.6. Preclinical Stage Partnering By Disease Type
6.7. Partnering By Preclinical Stage Technology Type
chapter 7 – Trends In Clinical Stage Deal Making
7.1. Introduction
7.2. Clinical Stage Partnering Over The Years
7.2.1. Trends In Phase I Deals Since 2007
7.2.1.1. Attributes Of Phase I Deals
7.2.2. Trends In Phase Ii Deals Since 2007
7.2.2.2. Attributes Of Phase Ii Deals
7.2.3. Trends In Phase Iii Deals Since 2007
7.2.3.1. Attributes Of Phase Iii Deals
7.3. Big Pharma Clinical Stage Dealmaking Activity
7.4. Big Biotech Clinical Stage Dealmaking Activity
7.5. Clinical Stage Partnering By Deal Type
7.6. Clinical Stage Partnering By Disease Type
7.7. Partnering By Clinical Stage Technology Type
chapter 8 – Average Payment Terms For Discovery, Preclinical And Clinical Stage Partnering
8.1. Introduction
8.2. Guidelines For Discovery, Preclinical And Clinical Stage Payment Terms
8.2.1. Upfront Payments
8.2.2. Milestone Payments
8.2.3. Royalty Payments
8.3. Discovery, Preclinical And Clinical Stage Payment Terms – Deal Data Analysis
8.3.1. Public Data
8.3.2. Survey Data
8.4. Payment Terms Analysis
8.4.1. Discovery, Preclinical And Clinical Stage Headline Values
8.4.2. Discovery, Preclinical And Clinical Stage Upfront Payments
8.4.3. Discovery, Preclinical And Clinical Stage Milestone Payments
8.4.4. Discovery, Preclinical And Clinical Stage Royalty Rates
chapter 9 – Leading Discovery, Preclinical And Clinical Stage Deals
9.1. Introduction
9.2. Top Discovery Stage Deals By Value
9.3. Top Preclinical Stage Deals By Value
9.4. Top Clinical Stage Deals By Value
chapter 10 – Big Pharma And Big Biotech Discovery, Preclinical And Clinical Stage Partnering Deals
10.1. Introduction
10.2. How To Use Big Pharma/big Biotech Partnering Deals
10.3. Big Pharma Discovery, Preclinical And Clinical Stage Partnering Company Profiles
abbott
actavis (merged With Watson Pharmaceuticals Oct 2012)
actelion
allergan
amgen
aspen Pharmacare
astellas
astrazeneca
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
4. baxter International
bayer
biogen Idec
boehringer Ingelheim
bristol-myers Squibb
celgene
csl
daiichi Sankyo
dainippon Sumitomo
eisai
eli Lilly
endo Pharmaceuticals
forest Laboratories
galderma
gilead Sciences
glaxosmithkline
grifols
hospira
johnson & Johnson
kyowa Hakko Kirin
lundbeck
menarini
merck & Co
merck Kgaa
mitsubishi Tanabe
mylan
novartis
novo Nordisk
otsuka
pfizer
purdue
roche
sanofi
servier
shionogi
shire
takeda
teva
ucb
valeant
warner Chilcott
10.4. Big Biotech Clinical Stage Partnering Company Profiles
acorda Therapeutics
actelion
alexion Pharmaceuticals
alkermes
alnylam Pharmaceuticals
amag Pharmaceuticals
amgen
amylin Pharmaceuticals
anika Therapeutics
bavarian Nordic
biocon
biocryst Pharmaceuticals
biogen Idec
biomarin Pharmaceuticals
biota Holdings
cangene
celgene
csl
cubist
elan
emergent Biosolutions
enzo Biochem
enzon Pharmaceuticals
exelixis
genmab
gilead Sciences
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
5. immunomedics
intermune
isis Pharmaceuticals
morphosys
nektar Therapeutics
nps Pharmaceuticals
onyx Pharmaceuticals
pdl Biopharma
questcor Pharmaceuticals
regeneron Pharmaceuticals
roche
sciclone Pharmaceuticals
seattle Genetics
spectrum Pharmaceuticals
targacept
the Medicines Company
ucb
united Therapeutics
vertex Pharmaceuticals
viropharma
chapter 11 – Discovery Stage Partnering Contracts Directory
11.1. Introduction
11.2. Company A-z
11.3. By Deal Type
11.4. By Stage Of Development
11.5. By Therapy Area
chapter 12 – Preclinical Stage Partnering Contracts Directory
12.1. Introduction
12.2. Company A-z
12.3. By Deal Type
12.4. By Stage Of Development
12.5. By Therapy Area
chapter 13 – Clinical Stage Partnering Contracts Directory
13.1. Introduction
13.2. Company A-z
13.3. By Deal Type
13.4. By Stage Of Development
13.5. By Therapy Area
about Wildwood Ventures
current Partnering
current Agreements
recent Titles From Current Partnering
order Form – Reports
order Form – Reports
order Form – Therapy Reports
appendices
introduction
appendix 1 – Directory Of Discovery Stage Deals By Company A-z 2007-2013
appendix 2 – Directory Of Discovery Stage Deals By Deal Type 2007-2013
appendix 3 – Directory Of Discovery Stage Deals By Therapy Area 2007-2013
appendix 4 – Directory Of Preclinical Stage Deals By Company A-z 2007-2013
appendix 5 – Directory Of Preclinical Stage Deals By Deal Type 2007-2013
appendix 6 – Directory Of Preclinical Stage Deals By Therapy Area 2007-2013
appendix 7 – Directory Of Clinical Stage Deals By Company A-z 2007-2013
appendix 8 – Directory Of Clinical Stage Deals By Deal Type 2007-2013
appendix 9 – Directory Of Clinical Stage Deals By Therapy Area 2007-2013
appendix 10 – Partnering Resource Center
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
6. online Partnering
partnering Events
further Reading On Dealmaking
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech